The growth of prostate acini from single cell implants in mice is a major breakthrough. Such results have important clinical implications, and will ultimately change the treatment paradigm for prostatic disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Leong, K. G., Wang, B. E., Johnson, L. & Gao, W. Q. Generation of a prostate from a single adult stem cell. Nature 456, 804–808 (2008).
Isaacs, J. T. & Coffey, D. S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 2, 33–50 (1989).
Burger, P. E. et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc. Natl Acad. Sci. USA 102, 7180–7185 (2005).
Collins, A. T., Habib, F. K., Maitland, N. J. & Neal, D. E. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. J. Cell Sci. 114, 3865–3872 (2001).
Richardson, G. D. et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 3539–3545 (2004).
Niu, Y. et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc. Natl Acad. Sci. USA 105, 12188–12193 (2008).
Van der Aa, F., Roskams, T., Blyweert, W. & De Ridder, D. Institial cells in the human prostate: a new therapeutic target. Prostate 56, 250–255 (2003).
Karbanová, J. et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J. Histochem. Cytochem. 56, 977–993 (2008).
Grisanzio, C. & Signoretti, S. p63 in prostate biology and pathology. J. Cell. Biochem. 103, 1354–1368 (2008).
Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 28, 2862–2870 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N. J. Maitland declared that he is a stockholder/director of Pro-Cure Therapeutics, which owns a patent portfolio relating to potential prostate drug targets. AT Collins and NJ Maitland have declared that they hold patents associated with the Pro-Cure Therapeutics portfolio.
Rights and permissions
About this article
Cite this article
Collins, A., Maitland, N. Regeneration of interest in the prostate. Nat Rev Urol 6, 184–186 (2009). https://doi.org/10.1038/nrurol.2009.48
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.48
This article is cited by
-
Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype?
Hormones and Cancer (2011)